成人肥胖的当代药物、器械与外科治疗
肥胖管理目标是改善健康,持续减重超过总体重10%可改善多种并发症及生活质量。维持减重是主要挑战,需长期多模式管理并权衡各疗法获益与风险。生活方式干预联合抗肥胖药物和减重手术可改善体重维持;新一代高效药物使超过三分之二临床试验参与者减重超过10%,长期安全性及心血管结局数据待报告。
要点
- 持续减重超过总体重10%可改善2型糖尿病、高血压、脂肪肝和阻塞性睡眠呼吸暂停等并发症及生活质量。
- 多数现有抗肥胖药物作用于中枢食欲通路以减少饥饿和食物奖励。
- 减重手术通常带来约25%的持久减重及肥胖并发症快速持续改善,但尚未与新一代高效药物比较。
核心结论
- 肥胖管理需长期多模式方法,结合生活方式干预、抗肥胖药物和减重手术以改善体重维持及健康获益。
研究设计与样本
- 综述,未报告系统检索范围。
主要发现
- 持续减重超过总体重10%可改善2型糖尿病、高血压、脂肪肝和阻塞性睡眠呼吸暂停等并发症及生活质量。
- 多数现有抗肥胖药物作用于中枢食欲通路以减少饥饿和食物奖励。
- 过去5年出现了针对单基因肥胖的靶向治疗和新一代抗肥胖药物。
- 新一代高效抗肥胖药物使超过三分之二临床试验参与者减重超过总体重10%。
- 长期研究显示减重手术通常带来约25%的持久减重及肥胖并发症快速持续改善。
临床怎么用
- 原文未据此给出推荐。
局限性
- 减重手术尚未与新一代高效抗肥胖药物进行比较。
- 原文指出尚待新一代高效抗肥胖药物的长期安全性、疗效和心血管结局数据。
- 原文指出需进一步研究以确定最佳患者个体化治疗策略,包括生活方式干预、抗肥胖药物、内镜和减重手术的组合,并确保公平获得有效治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The goal of obesity management is to improve health. Sustained weight loss of more than 10% overall bodyweight improves many of the complications associated with obesity (eg, prevention and control of type 2 diabetes, hypertension, fatty liver disease, and obstructive sleep apnoea), as well as quality of life. Maintenance of weight loss is the major challenge of obesity management. Like all chronic diseases, managing obesity requires a long-term, multimodal approach, taking into account each individual's treatment goals, and the benefit and risk of different therapies. In conjunction with lifestyle interventions, anti-obesity medications and bariatric surgery improve the maintenance of weight loss and associated health gains. Most available anti-obesity medications act on central appetite pathways to reduce hunger and food reward. In the past 5 years, therapeutic advances have seen the development of targeted treatments for monogenic obesities and a new generation of anti-obesity medications. These highly effective anti-obesity medications are associated with weight losses of more than 10% of overall bodyweight in more than two-thirds of clinical trial participants. Long-term data on safety, efficacy, and cardiovascular outcomes are awaited. Long-term studies have shown that bariatric surgical procedures typically lead to a durable weight loss of 25% and rapid, sustained improvements in complications of obesity, although they have not yet been compared with new-generation highly effective anti-obesity medications. Further work is required to determine optimal patient-specific treatment strategies, including combinations of lifestyle interventions, anti-obesity medications, endoscopic and bariatric surgical procedures, and to ensure equitable access to effective treatments.
引用
- Perdomo CM, Cohen RV, Sumithran P, et al. Contemporary medical, device, and surgical therapies for obesity in adults. Lancet. 2023. PMID: 36774932. doi:10.1016/S0140-6736(22)02403-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。